Login
$OPRX
$9.06 -$0.01 (0.11%) Close

Company Executives

$OPRX Management Team

Mr. Brendan Merrell

Chief Operating Officer

Age 40
Compensation -
Sex Male

Mr. Doug Besch

Chief Product Officer and Chief Technology Officer

Age 43
Compensation -
Sex Male

Mr. Andy D'Silva

Chief Business Officer

Age -
Compensation -
Sex Male

Ms. Theresa Greco

Chief Commercial Officer

Age 52
Compensation -
Sex Female

Ms. Lynn Vos

Independent Chairperson of the Board

Age 69
Compensation $249.0K USD
Sex Female

Mr. Stephen Silvestro

President

Chief Executive Officer

Director

Age 47
Compensation $973.1K USD
Sex Male

Mr. Edward Stelmakh

Chief Financial & Strategic Officer

Age 59
Compensation $1.009M USD
Sex Male

Ms. Marion Odence-Ford

General Legal Officer and Chief Human Resources Officer

Age 60
Compensation $2.478M USD
Sex Female
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
5.3 years
from year joined
CEO also chairs the board
No
Lynn O’Connor Vos
Director Age On board Independent Committees Other public boards 2025 pay Source
Lynn O’Connor Vos
70 2015
11 years
Independent None stated None stated $268,994
Catherine Klema
67 2024
2 years
Independent None stated None stated $227,994
James Lang
61 2017
9 years
Independent None stated None stated $203,994
Patrick Spangler
70 2018
8 years
Independent None stated None stated $234,994
Mariyamma Varghese Presti
52 2026
0 years
Independent None stated None stated Not stated
Gregory Wasson
67 2020
6 years
Independent None stated None stated $200,994
Stephen Silvestro
48 2025
1 year
Not independent None stated None stated Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 30, 2026
James Lang
one of our Board Members; formerly Chief Executive Officer of Eversana Life Science Services, LLC and now serves on EVERSANA's Board of Directors
$922,416 and $375,280
2025 and 2024

Reseller Agreement under which EVERSANA may offer OptimizeRx solutions to its life sciences customers, generating revenue for OptimizeRx

With EVERSANA Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support